PPIDT00458
Drug Information
| Name | Naxitamab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB15965 |
| Type | biotech |
| Indication | Naxitamab-gqgk is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of patients 1 year of age and older with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.[L24454] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Intravenous |
40 mg/10mL
|
Target Information
| Role | Uniprot_ID | Gene_Name | Entity_Name | Organism | Actions | Internal link |
|---|---|---|---|---|---|---|
| No target records. | ||||||